Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 54.72 [1][5] Core Views - The company's performance in 2025 met expectations, with revenue of RMB 31 billion (up 11% year-on-year) and net profit of RMB 4.1 billion (up 31% year-on-year). The fourth quarter of 2025 saw revenue of RMB 7 billion (down 5% year-on-year, down 10% quarter-on-quarter) and net profit of RMB 800 million (up 3% year-on-year, down 28% quarter-on-quarter) [1] - The company is expected to maintain high growth in its refrigeration and automotive businesses, with a focus on entering the bionic robot electromechanical actuator industry [1] Business Overview - The refrigeration business generated revenue of RMB 18.6 billion (up 12% year-on-year) with a gross margin of 28.8% (up 1.4 percentage points year-on-year). This growth is attributed to the company's focus on core customers and expansion into new application areas such as data centers [2] - The automotive parts business achieved revenue of RMB 12.4 billion (up 9% year-on-year) with a gross margin of 28.8% (up 1.2 percentage points year-on-year). The business improved operational efficiency and accelerated digital transformation and AI technology application [2] Financial Performance - The company successfully transitioned from a "land grab" strategy to a "refined cultivation" strategy, focusing on cost targets, comprehensive cost reduction, organizational optimization, and efficiency improvements, resulting in profit growth. The overall gross margin reached 28.8% in 2025, an increase of 1.3 percentage points year-on-year [3] - The expense ratios for sales, management, and R&D were 2.4%, 6.1%, and 4.4%, respectively, showing improvements of -0.2, -0.2, and -0.4 percentage points year-on-year [3] Outlook - For 2026, the company is expected to continue high growth across all segments, with data center revenue projected to grow by over 50%. The company will focus on enhancing product capabilities and global operational capacity while expanding overseas production in countries like Mexico, Poland, Vietnam, and Thailand [4] - The company aims to strengthen its position in the new energy vehicle market, with domestic and international demand expected to increase due to rising global oil prices [4] Earnings Forecast and Valuation - Revenue forecasts for 2026 and 2027 are RMB 36.1 billion and RMB 44.3 billion, respectively, with a new forecast for 2028 at RMB 48.9 billion. Net profit forecasts for 2026 and 2027 are RMB 4.8 billion and RMB 5.8 billion, respectively, with a new forecast for 2028 at RMB 6.3 billion [5] - The company is assigned a premium of 5% on its main business due to rapid breakthroughs in the data center business and clearer growth trajectories in the robotics sector, leading to a target price of RMB 54.72 [5]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 20.92 [1]. Core Insights - The company reported a revenue of RMB 43.225 billion for the year 2025, reflecting a year-on-year increase of 1.1%. However, the core operating profit decreased to RMB 5.403 billion, down 13.3% year-on-year, resulting in a core operating profit margin of 12.5%, which is a decline of 2.1 percentage points [6]. - The company has initiated the "Pomegranate Plan" and the "Different Haidilao" strategy, which have shown improvements in same-store turnover and customer spending in the second half of 2025. The multi-brand matrix and takeaway business have significantly contributed to revenue growth [6][9]. - The company plans to continue restructuring its organizational framework to strengthen its competitive advantage and accelerate growth in its second growth curve [6]. Financial Performance Summary - For the fiscal year 2025, the company achieved a revenue of RMB 43.225 billion, with a core operating profit of RMB 5.403 billion and a net profit attributable to the parent company of RMB 4.050 billion [6][10]. - The company’s revenue growth is projected to continue, with estimates of RMB 46.114 billion for 2026, RMB 47.795 billion for 2027, and RMB 48.750 billion for 2028, reflecting growth rates of 6.68%, 3.65%, and 2.00% respectively [5][10]. - The earnings per share (EPS) is expected to increase from RMB 0.73 in 2025 to RMB 0.89 by 2028 [10]. Operational Insights - The company’s direct restaurant revenue for 2025 was RMB 37.543 billion, accounting for 86.9% of total revenue, while franchise revenue surged by 1519% to RMB 27 million, and takeaway revenue increased by 111.9% to RMB 2.658 billion [7]. - The average customer spending in self-operated restaurants was RMB 97.7, showing a slight increase of 0.2% year-on-year, while the same-store daily sales decreased by 6.7% year-on-year [7]. - The company opened 54 new self-operated stores in the second half of 2025, accelerating its expansion compared to the first half [9]. Profitability and Valuation - The overall gross margin for the year was 59.5%, down 2.6 percentage points year-on-year, primarily due to changes in revenue structure and the introduction of higher-quality menu items [8]. - The company’s price-to-earnings (PE) ratio is projected to be 19.37 for 2025, decreasing to 15.78 by 2028, while the price-to-book (PB) ratio is expected to decline from 7.83 to 6.10 over the same period [5][10]. - The dividend payout ratio remains high at 87%, with a proposed final dividend of HKD 0.384 per share [6].

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 17.91 [6]. Core Insights - The company reported a revenue of RMB 2.389 billion for 2025, a year-on-year decrease of 28.65%, and a net profit attributable to shareholders of RMB 113 million, down 62.91% year-on-year [1][11]. - In Q4 2025, the company achieved a revenue of RMB 639 million, which represents a year-on-year decrease of 35.78% but a quarter-on-quarter increase of 19.00% [1]. - The company signed new orders worth RMB 2.664 billion in 2025, with Q4 new orders reaching RMB 1.051 billion, a quarter-on-quarter increase of 96.8%, indicating a potential recovery in demand for tank containers [4]. Business Segment Summary - The tank container business generated RMB 1.790 billion in revenue for 2025, a decline of 34.89% year-on-year, primarily due to insufficient operations in the downstream chemical industry and weak logistics demand [2]. - The medical equipment components segment saw revenue of RMB 253 million, reflecting a steady growth of 5.02% year-on-year [2]. - The aftermarket business generated RMB 148 million in revenue, with a slight increase of 0.22% year-on-year [2]. Financial Performance Summary - The company's gross margin for 2025 was 14.00%, down 2.67 percentage points year-on-year, attributed to weak demand in the tank container industry and increased competition [3]. - The total expense ratio for 2025 was 9.21%, an increase of 4.63 percentage points year-on-year, driven by higher foreign exchange losses and financial expenses [3]. - The company forecasts a net profit of RMB 316.83 million for 2026, representing a significant recovery of 181.08% year-on-year [9].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 23.88 [8]. Core Views - The company achieved a revenue of RMB 1.9 billion in 2025, a decrease of 28.02% year-on-year, with a net profit attributable to shareholders of RMB 61.45 million, down 38.89% year-on-year. The fourth quarter saw a revenue of RMB 578 million, with a year-on-year decline of 34.49% but a quarter-on-quarter increase of 106.48% [1][8]. - The company’s gross margin improved significantly to 19.48% in 2025, an increase of 3.24 percentage points year-on-year, attributed to the integration of construction and production management platforms that enhanced operational efficiency [2]. - The demand for FPSO (Floating Production Storage and Offloading) units is expected to rise due to ongoing high demand in deep-sea oil and gas development, driven by geopolitical tensions and the need for energy security [3]. - The company has a robust order backlog, including contracts for FPSO projects in Suriname and Guyana, which will support its performance in 2026 [4]. - A strategic partnership with SBM Offshore N.V. is expected to enhance the company's capabilities and allow it to participate in more high-end projects, capitalizing on the favorable market conditions for FPSO equipment [5]. Financial Forecasts and Valuation - The company’s net profit forecasts for 2026 and 2027 are RMB 149 million and RMB 330 million, respectively, with an expected net profit of RMB 456 million in 2028. The corresponding book values per share (BPS) are projected to be RMB 11.94, RMB 13.11, and RMB 14.73 for the years 2026, 2027, and 2028 [6]. - The report assigns a price-to-book (PB) ratio of 2.0 for 2026, reflecting the company's position as a leading FPSO module manufacturer benefiting from increasing demand in deep-sea oil and gas development [6].

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of RMB 29.76 and HKD 28.93 [7]. Core Views - The company reported a revenue of RMB 82.532 billion for 2025, a year-on-year decrease of 9.33%, while the net profit attributable to shareholders was RMB 8.113 billion, an increase of 5.42% year-on-year [1]. - The company plans to distribute a final dividend of RMB 0.61 per share, raising the total cash dividend payout ratio to 55.3%, marking the first time it has exceeded 50% [1]. - Despite industry demand pressures, the company is expected to achieve stable profit growth through cost control and reduced capital expenditures [1]. Summary by Sections Revenue and Profitability - The company achieved a revenue of RMB 82.532 billion in 2025, down 9.33% year-on-year, with a net profit of RMB 8.113 billion, up 5.42% year-on-year [1]. - The fourth quarter revenue was RMB 21.234 billion, showing a quarter-on-quarter increase of 6.14%, while the net profit was RMB 1.809 billion, down 6.61% quarter-on-quarter [1]. Cost Control and Efficiency - The company’s self-produced cement clinker sales volume was 26.5 million tons in 2025, a decrease of 1.13% year-on-year, which is better than the national average decline of 6.9% [2]. - The comprehensive cost of self-produced cement clinker decreased by 11.12% year-on-year, with fuel and power costs down by 15.70% [2]. - The gross profit margin for self-produced cement was 27.76%, an increase of 2.95 percentage points year-on-year [2]. Business Segments Performance - The aggregate and manufactured sand segment saw a revenue of RMB 4.203 billion, down 10.41% year-on-year, with a gross margin of 40.13%, a decrease of 6.78 percentage points [3]. - The ready-mixed concrete business performed well, achieving a revenue of RMB 3.209 billion, up 20.04% year-on-year, with a gross margin of 12.38%, an increase of 2.38 percentage points [3]. - The company’s overseas and export business became significant growth drivers, with revenues of RMB 5.846 billion and RMB 0.673 billion, respectively, representing increases of 24.99% and 158.5% year-on-year [3]. Financial Health - The company maintained a net cash position with a net cash flow from operating activities of RMB 16.644 billion, despite a decrease due to reduced trade income [4]. - The debt-to-asset ratio at the end of 2025 was 20.42%, down 0.89 percentage points from the previous year, with cash and cash equivalents reaching RMB 50.252 billion [4]. - The company’s net debt ratio was -18.0%, continuing its net cash status since 2017 [4]. Earnings Forecast and Valuation - Due to ongoing weak downstream demand and rising raw material prices, the earnings forecasts for 2026 and 2027 have been revised downwards, with expected net profits of RMB 9.211 billion and RMB 10.074 billion, respectively [5]. - The estimated book value per share for 2026 is RMB 37.2, with target prices set at RMB 29.76 and HKD 28.93, corresponding to 0.8x and 0.7x the 2026 P/B ratio [5].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 317.68 [7][5]. Core Insights - The company achieved revenue and net profit of RMB 2.584 billion and RMB 820 million in 2025, representing year-on-year growth of 25.1% and 21.9% respectively, aligning with performance expectations [1]. - In Q4 2025, the company reported revenue and net profit of RMB 716 million and RMB 197 million, showing year-on-year increases of 32.4% and 36.1%, indicating a return to rapid growth [1]. - The gross margin for 2025 was 72.9%, up 0.6 percentage points year-on-year, driven by the strong performance of high-end new products [1]. - The company’s operating cash flow improved significantly, reaching RMB 968 million, a year-on-year increase of 30.2 [1]. Summary by Relevant Sections Electrophysiology Business - The electrophysiology segment generated revenue of RMB 571 million in 2025, with a year-on-year growth of 29.8%. In the second half of 2025, revenue surged by 50.3% [2]. - The company completed over 5,900 PFA pulse ablation surgeries and more than 15,000 traditional 3D electrophysiology surgeries, indicating increasing market acceptance [2]. - New product approvals in 2025 included high-density mapping catheters and pressure-sensing RF ablation catheters, enhancing the product matrix [2]. Other Business Segments - The coronary access segment reported revenue of RMB 1.343 billion in 2025, up 27.4% year-on-year, with an increase in hospital penetration [3]. - The peripheral intervention segment achieved revenue of RMB 456 million, reflecting a year-on-year growth of 29.8%, supported by an expansion of product categories [3]. - The non-vascular intervention segment saw revenue of RMB 52.59 million, growing 36.5% year-on-year, with expectations for systematic promotion in 2026 [3]. - The OEM segment experienced a decline in revenue to RMB 145 million, down 12.1% year-on-year, attributed to short-term fluctuations in downstream demand [3]. Incentive Plan - The company announced a restricted stock incentive plan for 2026, proposing to grant a total of 2.2 million shares, representing 1.56% of the total share capital, to 663 individuals, including key personnel [4]. - The performance targets for key personnel include achieving a revenue growth of at least 74.29% from 2025 to 2026-2027 and 214.97% from 2025 to 2028-2029, reflecting confidence in future high-quality development [4]. Profit Forecast and Valuation - The forecast for net profit attributable to the parent company for 2026-2028 is RMB 1.042 billion, RMB 1.321 billion, and RMB 1.657 billion, with slight adjustments of -3% and -5% for 2026 and 2027 respectively [5]. - The company is positioned as a leader in the domestic electrophysiology and vascular intervention sectors, with a competitive edge, warranting a 43x PE for 2026 [5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 43 HKD [7][19]. Core Insights - The company reported FY2025 revenue of 457.3 billion RMB, a year-on-year increase of 25.0%, and a Non-GAAP net profit of 39.2 billion RMB, up 43.8% year-on-year. The 4Q25 revenue was 116.9 billion RMB, with a year-on-year growth of 7.3%, while Non-GAAP net profit for the quarter was 6.3 billion RMB, down 23.7% year-on-year [1][5]. - Management indicated that the storage price increase cycle may last longer and be more significant than previously expected, potentially extending into 2027, which is a more pessimistic outlook compared to earlier reports [1]. - The company has made significant advancements in AI, with the MiMo-V2-Pro model ranking among the top globally and the AI Agent "MiKe" entering beta testing, although commercialization is still in its early stages [3]. - The automotive segment achieved its first annual operating profit, delivering 411,082 vehicles, a 200.4% increase year-on-year, with the new SU7 model performing exceptionally well [4]. Summary by Sections Financial Performance - FY2025 revenue reached 457.3 billion RMB, with a 25.0% year-on-year increase. Non-GAAP net profit was 39.2 billion RMB, reflecting a 43.8% increase year-on-year. The 4Q25 revenue was 116.9 billion RMB, up 7.3% year-on-year, while Non-GAAP net profit for the quarter was 6.3 billion RMB, down 23.7% year-on-year [1][5]. Smartphone/IoT/Internet Business - In 4Q25, the smartphone and AIoT segment generated revenue of 79.7 billion RMB, a decrease of 13.7% year-on-year, with a gross margin of 20.0%. Smartphone revenue was 44.3 billion RMB, with a shipment of 37.7 million units, down 11.6% year-on-year. IoT revenue was 24.6 billion RMB, down 20.3% year-on-year, but the annual IoT revenue reached a record high of 123.2 billion RMB [2]. AI Development - The company launched several AI models, including MiMo-V2-Pro, MiMo-V2-Omni, and MiMo-V2-TTS, establishing a comprehensive AI technology foundation. The MiMo-V2-Pro model has the highest usage on the OpenRouter platform, priced significantly lower than competitors [3]. Automotive Business - The automotive segment achieved its first annual operating profit with a delivery of 411,082 vehicles, exceeding the initial target of 300,000 units. The new SU7 model saw strong demand, with over 15,000 orders within 34 minutes of launch [4]. Profit Forecast and Valuation - The report maintains Non-GAAP net profit forecasts of 34.5 billion RMB for 2026 and 45.4 billion RMB for 2027, introducing a forecast of 57.1 billion RMB for 2028. The target price of 43 HKD corresponds to a 32x PE ratio for 2026 [5][19].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 52.75 [6]. Core Insights - The company reported revenue and net profit for 2025 of HKD 525.5 billion and HKD 158.7 billion, respectively, representing year-on-year growth of 22.5% and 30.9%. The second half of 2025 saw revenue and net profit of HKD 269.3 billion and HKD 81.8 billion, respectively, exceeding previous expectations [1][4]. - The packaging water business has shown a recovery with a revenue increase of 17.3% year-on-year, while the ready-to-drink tea segment has experienced a revenue growth of 29.0% year-on-year, indicating strong market penetration and brand strength [2][3]. Summary by Sections Revenue and Profit Performance - For 2025, the company achieved revenue of HKD 525.5 billion and net profit of HKD 158.7 billion, with growth rates of 22.5% and 30.9% year-on-year. The second half of 2025 saw revenue and net profit of HKD 269.3 billion and HKD 81.8 billion, respectively, with year-on-year growth of 30.0% and 39.0% [1]. - The packaging water segment generated revenue of HKD 187.1 billion in 2025, up 17.3% year-on-year, while the ready-to-drink tea segment reached HKD 216.0 billion, reflecting a growth of 29.0% [2]. Profitability Metrics - The gross margin for 2025 increased by 2.4 percentage points to 60.5%, driven by lower raw material costs and improved production efficiency. The net profit margin also rose by 1.9 percentage points to 30.2% [3]. - The EBIT profit margins for packaging water, ready-to-drink tea, functional beverages, and juice segments improved significantly, indicating enhanced profitability across the board [3]. Earnings Forecast and Valuation - The company has strong fundamentals, with revised profit forecasts for 2026 and 2027 at HKD 179.7 billion and HKD 202.3 billion, respectively. The estimated EPS for 2026 is HKD 1.60, with a target PE ratio of 30x, leading to a target price of HKD 52.75 [4][6].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 19.69 [6][4]. Core Insights - The company has shown robust performance driven by three main business segments: Adult Nutrition (ANC), Infant Nutrition (BNC), and Pet Nutrition (PNC). In 2025, the company achieved revenues of RMB 14.35 billion, net profit of RMB 200 million, and adjusted comparable net profit of RMB 660 million, reflecting year-on-year growth of 10.0%, a turnaround from loss, and an increase of 22.7% respectively [1][3]. - The company is expected to continue its steady growth in 2026, particularly in the ANC and PNC segments, with the infant formula business anticipated to recover further. The company is also focusing on debt reduction, having reduced total debt by over RMB 600 million during the year [1][4]. Summary by Relevant Sections Financial Performance - In 2025, the company reported a gross margin increase of 1.8 percentage points to 62.4%, driven by improved margins in the ANC and PNC segments and optimized procurement costs [3]. - The adjusted comparable EBITDA margin decreased by 0.7 percentage points to 14.3%, with variations across business segments: ANC at 19.9%, BNC at 11.4%, and PNC at 3.1% [3]. - The company ended 2025 with a cash balance exceeding RMB 1.7 billion and a net leverage ratio reduced from 3.99 times in 2024 to 3.45 times in 2025 [1][3]. Business Segment Performance - In 2025, the ANC segment revenue grew by 4.4%, with notable growth in the Chinese market at 13.3%, while the Australian and New Zealand market saw a decline of 21.8% due to a strategic reduction in purchasing business [2]. - The BNC segment showed significant recovery, with infant formula revenue increasing by 26.5% and probiotics and nutritional supplements for infants growing by 2.0% [2]. - The PNC segment reported a revenue increase of 8.7%, with growth in mainland China at 8.6% and North America at 7.8% [2]. Profit Forecast and Valuation - The profit forecast for 2026-2027 has been slightly raised, with expected net profits of RMB 730 million and RMB 860 million, representing increases of 13% and 16% respectively from previous estimates [4]. - The estimated EPS for 2026, 2027, and 2028 is projected at RMB 1.12, RMB 1.34, and RMB 1.48 respectively, with a reference PE ratio of 16x for 2026 [4][10].

Investment Rating - The report maintains an "Accumulate" rating for the company [8] Core Insights - The company achieved a revenue of 3.432 billion RMB in 2025, representing a year-on-year increase of 94.3%, with a net profit attributable to shareholders of 194 million RMB, up 84.0% year-on-year [1][6] - The company is actively expanding its own brand health products and has made strategic acquisitions to enhance brand management capabilities, which are expected to capture industry growth opportunities [1][6] - The brand "Zhenjia" has launched over 20 types of fragrance laundry liquids and has seen significant growth in both online and offline channels, with a GMV increase of over 80% during the Double 11 shopping festival [2][3] Revenue and Profitability - The company’s gross margin for 2025 was 59.80%, an increase of 15.2 percentage points year-on-year [5] - The revenue from brand management business reached 895 million RMB in 2025, growing by 78.63% year-on-year, while the agency operation business generated 723 million RMB, a decrease of 10.25% year-on-year [4] Future Projections - The forecast for the company's net profit attributable to shareholders is adjusted to 280 million RMB for 2026 and 439 million RMB for 2027, reflecting increases of 7.1% and 8.9% respectively [6] - The target market capitalization is set at 17.617 billion RMB, with a target price of 56.64 RMB per share [6] Market Positioning - The company has positioned its brands "Feicui" and "NuiBei" to target the health and wellness market, with significant online sales growth observed [3][4] - The strategic partnership with the oral beauty brand "Meisidike" is expected to further enhance the brand management business [4]